These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36660611)

  • 1. Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature.
    Yan J; Ma N; Qiao WL; Liu KQ; Liu DW; Wang Y; Qiao TT; Hao XQ; Zheng MD
    Ann Transl Med; 2022 Dec; 10(24):1411. PubMed ID: 36660611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractory pruritus caused by sintilimab and its clinical management: A case report.
    Chen L; Cao X; Luo X; Jiang T
    Heliyon; 2024 Jul; 10(14):e34107. PubMed ID: 39100464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
    Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
    Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events.
    Tu L; Ye Y; Tang X; Liang Z; You Q; Zhou J; Pan Z
    Front Oncol; 2021; 11():757069. PubMed ID: 35004277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
    Lu S; Wu L; Jian H; Cheng Y; Wang Q; Fang J; Wang Z; Hu Y; Han L; Sun M; Miao L; Ding C; Cui J; Wang K; Li B; Li X; Ye F; Liu A; Pan Y; Cang S; Zhou H; Sun X; Shen Y; Wang S; Zhang W; He Y
    Lancet Respir Med; 2023 Jul; 11(7):624-636. PubMed ID: 37156249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: A rare case of sintilimab-induced gastric stenosis and literature review.
    Song K; Dong H; Jiang S; Xu X; Zhang C; Chen Q; Wang Q
    Front Oncol; 2023; 13():1091459. PubMed ID: 36761970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
    Molife C; Brnabic A; Stefaniak VJ; Belger MA; Gruver K; Chen JV; Souri S; Blumenschein GR
    Immunotherapy; 2023 Mar; 15(4):293-309. PubMed ID: 36748406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE).
    Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q
    J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: A rare case of anti-PD-1 sintilimab-induced agranulocytosis/severe neutropenia in non-small cell lung cancer and literature review.
    Qin Y; Lu S; Chen J; Peng J; Yang J
    Front Oncol; 2024; 14():1415748. PubMed ID: 38957321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review.
    Zhou Q; Qin Z; Wu G; Yan P; Wang Q; Qu J; Jiang J; Ye D
    Front Oncol; 2024; 14():1465395. PubMed ID: 39351355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
    Lu Z; Wang J; Shu Y; Liu L; Kong L; Yang L; Wang B; Sun G; Ji Y; Cao G; Liu H; Cui T; Li N; Qiu W; Li G; Hou X; Luo H; Xue L; Zhang Y; Yue W; Liu Z; Wang X; Gao S; Pan Y; Galais MP; Zaanan A; Ma Z; Li H; Wang Y; Shen L;
    BMJ; 2022 Apr; 377():e068714. PubMed ID: 35440464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of immune-related lichenoid dermatitis by Weiling decoction in a patient with non-small cell lung cancer: A case report and review of literature.
    Liu Y; Tang J; Yu LY; Jiang Q
    Explore (NY); 2023; 19(5):730-735. PubMed ID: 36878772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report.
    Li H; Mu F; Zou B; Wang L
    Medicine (Baltimore); 2023 Aug; 102(31):e34432. PubMed ID: 37543824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.
    Ai Q; Chen W; Li Y; Li G
    Front Immunol; 2022; 13():840916. PubMed ID: 35720298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
    Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
    BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
    Li G; Gong S; Wang N; Yao X
    Front Immunol; 2022; 13():989966. PubMed ID: 36090976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide, cisplatin, and sintilimab combined with anlotinib in successful treatment of adrenocortical carcinoma with lung metastasis: a case report.
    Niu W; Zhang H; Ma X; Liang H; Qiao Z; Wang Z; Niu L
    Front Oncol; 2024; 14():1403762. PubMed ID: 39220648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.
    Jiang Z; Chen X; Sun Z; Shen X; Huang Y; Liu J
    J Inflamm Res; 2023; 16():5061-5067. PubMed ID: 37936597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.